Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Earnings upgrade strategy produces tasty results

There is a growing trend for companies to report better than expected earnings and this is something that investors should follow. Earnings growth is one of the strongest catalysts for share price growth, so it pays to watch the companies doing well operationally and financially.
Beating estimates in the current environment could be down to several reasons including management being too cautious following the first lockdown and underestimating the potential for earnings to recover.
Analysts have been slow to upgrade their forecasts, perhaps also due to being too cautious, and therefore the market consensus has been too low for many stocks.
In July, we wrote an article about how stocks with the largest upward earnings revisions often go on to significantly beat the average market return over a three-month period.
In that article we published a list of stocks that had seen the biggest earnings upgrades by analysts over the previous month. From that list, 15 of the 20 stocks subsequently beat the market’s 5% gain as measured by the FTSE All-Share. Many of the stocks outperformed by a significant margin.
Trackwise Designs (TWD:AIM) increased by 256% between 14 July and 20 November.
The company had already seen upgrades following 2019 results which helped put it on our original list of stocks with earnings momentum. It then won an important contract in September with an electric vehicle manufacturer, which triggered further earnings upgrades and put the stock on the radar of more investors.
Buying stocks with the biggest earnings upgrades isn’t a guaranteed winning strategy. For example, education specialist RM (RM.) has lost 25.7% since our July article. However, the average return from the 20 stocks was 38% in the period, showing how diversification can benefit this strategy.
While there are recent examples of companies giving more optimistic commentary on their outlook, in general we would expect ongoing caution from most management teams while lockdown restrictions are still in place.
Such caution could easily change upon the approval of a Covid-19 vaccine, but for now we think there is the potential for more companies to beat expectations with trading. The stocks with the biggest upgrades over the past month feature in the accompanying table if you want to consider the earnings momentum investment strategy.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Editor's View
Feature
First-time Investor
Great Ideas
- Boston Scientific has big potential to get back on top in 2021
- Buy this trust to access cut-price quality names
- Take advantage of share price pullback to buy more Softcat stock
- Strong trading could lead to more generous dividends for Somero
- Reasons to be more optimistic on AG Barr
- Odyssean Investment Trust sails in with swift 17.4% return
Investment Trusts
Money Matters
News
- Sunak pledges increased spending on jobs, housing and infrastructure
- Germany’s blue-chip index gets big overhaul after Wirecard scandal
- Controversial fast-track funding rule scrapped
- Blue Prism eyes US listing to help narrow valuation gap
- Worst of dividend cuts ‘now over’ says Janus Henderson
- Video game platform Roblox could see blockbuster market debut
- Mute reaction to AstraZeneca vaccine is no reason to lose optimism
- UK ‘green revolution’ could be great for investors